287 results about "Intracerebral hemorrhage" patented technology

An ultrasound catheter with fluid delivery lumens, fluid evacuation lumens and a light source is used for the treatment of intracerebral hemorrhages. After the catheter is inserted into a blood clot in the brain, a lytic drug can be delivered to the blood clot via the fluid delivery lumens while applying ultrasonic energy to the treatment site. As the blood clot is dissolved, the liquefied blood clot can be removed by evacuation through the fluid evacuation lumens.

The invention discloses a treating method of CT cerebral hemorrhage image, comprising: automatically selecting gray level image, binary image of brain tissue or binary image of head of raw data based on nonsingular number and winkling the brain median sagittal plane based on singular number; robustly depicting the asymmetry of instant cerebral hemorrhage to the median sagittal plane based on general asymmetry of dotted pairs area; adaptively figuring out gray threshold of instant cerebral hemorrhage, threshold of general asymmetry, local contrast threshold and partial bulk effect threshold; determining threshold of instant cerebral hemorrhage near the fourth ventricle by searching the axial slice below the pertrous bone; obtaining instant cerebral hemorrhage symmetrical to the median sagittal plane from the obtained unsymmetric hemorrhage; determining darker instant cerebral hemorrhage from determined lighter (higher gray scale) instant cerebral hemorrhage; removing high signal of not instant cerebral hemorrhage; determining instant cerebral hemorrhage pixel due to partial bulk effect, therefore the final instant cerebral hemorrhage image is obtained.

A navigation system for intracerebral hemorrhage puncture surgery based on medical image model reconstruction and localization is disclosed in the embodiment of the invention, Positioned navigation system for intracerebral hemorrhage puncture surgery, including hosts, AR device and naked-eye 3D display device, The host computer receives the medical CT / MRI data of patients with intracerebral hemorrhage, reconstructs the model of multi-group patients with intracerebral hemorrhage, processes the model butt joint, obtains the three-dimensional virtual model of patients' skull and hematoma, and displays the three-dimensional virtual model on the naked eye 3D display device. The host computer receives the medical CT / MRI data of patients with intracerebral hemorrhage. According to the 3D virtualmodel and the angle depth information, the host computer simulates the operation navigation and connection to import the AR device. AR devices are used for feature point detection, spatial registration between virtual hematoma and real hematoma, real-time catheter tracking, holographic display of virtual hematoma and virtual catheter, voice and somatosensory interaction with physicians. The embodiment of the invention can reduce medical cost and provide human-computer interaction function.

The present invention relates to novel compounds of formula (I) and their pharmaceutical compositions. In addition, the present invention relates to therapeutic methods for the treatment and / or prevention of Aβ-related pathologies such as Downs syndrome, β-amyloid angiopathy such as but not limited to cerebral amyloid angiopathy or hereditary cerebral hemorrhage, disorders associated with cognitive impairment such as but not limited to MCI (“mild cognitive impairment”), Alzheimer Disease, memory loss, attention deficit symptoms associated with Alzheimer disease, neurodegeneration associated with diseases such as Alzheimer disease or dementia including dementia of mixed vascular and degenerative origin, pre-senile dementia, senile dementia and dementia associated with Parkinson's disease, progressive supranuclear palsy or cortical basal degeneration.

The present invention relates to the use of glial fibrillary acidic protein (GFAP) as a diagnostic marker for intracerebral hemorrhage. The invention especially relates to methods for the early detection of intracerebral hemorrhage. Such early and rapid detection can be performed rapidly e.g. by a test strip format assay. GFAP can be used as a stand-alone marker or in combination with one or more other markers.

A compound of Formula (I), or pharmaceutically acceptable salts and / or hydrates or prodrugs thereof, wherein Formula (I) has the structure:is provided, wherein R1-R7 are defined herein. These compounds are useful in medicaments for treating a disease selected from the group consisting of Alzheimer's Disease, amyloid angiopathy, cerebral amyloid angiopathy, systemic amyloidosis, hereditary cerebral hemorrhage with amyloidosis of the Dutch type, inclusion body myositis, mild cognitive impairment (MCI) and Down's syndrome, in a subject.

By introducing hepatocyte growth factor (HGF) gene and / or vascular endothelial growth factor (VEGF) gene into the subarachnoid space in humans, cerebrovascular disorders such as cerebrovascular obstruction, cerebral infarction, cerebral thrombosis, cerebral embolism, stroke, cerebral bleeding, moyamoya disease, cerebrovascular dementia, and Alzheimer's dementia can be effectively treated or prevented.

A method and devices are disclosed to detect bright brain regions (BBRs) from clinical non-enhanced computed tomography images through large grayscale, large grayscale asymmetry with respect to the midsagittal plane (MSP), and large grayscale local contrast. An adaptive approach is disclosed to determine thresholds of the 3 features and adjust the window width for data conversion. The substantial grayscale variability of BBRs for a subject is addressed by finding the bright portion followed by recovering. Those BBR voxels symmetrical to the MSP are recovered, partial volume effects are compensated and the high grayscale regions which may not correspond to intracerebral hemorrhage are excluded. The disclosed method and system could be a useful tool to aid classifying stroke types, quantifying intracerebral hemorrhage and enhancing stroke therapy.

The invention discloses a novel Chinese medicinal composition for treating intracerebral hemorrhage and a preparation method thereof. The Chinese medicinal composition is mainly prepared from the following raw material medicaments: charred sanguisorba root, Japanese thistle herb or root, common cephalanoplos herb, charred Chinese arborvitae twig, lalang grass rhizome, India madder root, cattail pollen, charred cattail pollen, rosewood heart wood, carbonized human hair, common bletilla pseudobulb, hairyvein agrimonia herb and bud, lotus rhizome node, plant soot, charred trachycarpus, motherwort herb, hiraute shiny bugleweed herb, chaff flower root, ground beetle, nacre, oyster shell, tall gastrodia tuber, gambir plant, earthworm, stiff silkworm, scorpion, Chinese angelica, white paeony root, grassleaf sweelflag rhizome, toad venom, borneol, camphor, radix rehmanniae preparata, tuber fleeceflower root, dendrobium, fragrant solomonseal rhizome, turtle shell, tortoise plastron, tangerine peel, nutgrass galingale rhizome, combined spicebush root, turmeric root-tuber, gypsum, anemarrhena asphodeloides bunge, gardenia jasminoides, baical skullcap root, lightyellow sophora root, fresh rehmannia, figwort root, and tree peony bark. The Chinese medicinal composition can be prepared into any common oral preparation by a conventional Chinese medicinal preparation method. The Chinese medicinal composition can obviously improve symptoms of numbness of the limbs, habit spasm, semiplegia, wind stroke with loss of speech, deviated eyes and mouth, gatism, obnubilation, elevation of blood pressure, elevation of intracranial pressure and the like, and has exact clinical curative effect, obvious curative effect and quick response. The Chinese medicinal composition is basically combined by adopting edible and pharmaceutical medicaments specified in national formulary, so that the Chinese medicinal composition has the advantages of low cost, nearly no toxic or side effects and the like.

The present invention is directed to methods for controlled and optimized removal of cerebrospinal fluid (CSF) from the CSF space of a patient. The methods are particularly intended for the treatment of Alzheimer's disease and other conditions which are caused by, or otherwise related to, the retention and / or accumulation of toxic substances in the CSF. One aspect of the present invention provides a method for shunting toxic substances present in a brain ventricle to the sinus system of an individual suffering from, or at risk of developing, a condition related to the retention and / or accumulation of toxic substances in the CSF, such as Alzheimer's disease. In addition to Alzheimer's disease, the present invention will be useful for treating other conditions resulting from the accumulation of toxic substances and resulting lesions in the patient's brain, such as Down's Syndrome, hereditary cerebral hemorrhage with amyloidosis of the Dutch-Type (HCHWA-D), epilepsy, narcolepsy, Parkinson's disease, polyneuropathies, multiple sclerosis, amyotrophic lateral sclerosis (ALS), myasthenia gravis, muscular dystrophy, dystrophy myotonic, other myotonic syndromes, polymyositis, dermatomyositis, brain tumors, Guillain-Barre-Syndrome, and the like.

The invention discloses a guiding stent which is obtained by the adoption of 3D printing technology and used for cerebral hemorrhage minimally invasive surgery and preparation method thereof. The preparation method comprises the steps of firstly, scanning the head of a hemorrhage patient so that head image file data can be obtained, then sorting the skull facial profile and target hematoma in need of removal, establishing a three-dimensional model which is closely attached to the skull face of the patient relative to the immobile area profile, designing a hollow non-closed-loop puncture guiding channel stent model in the model, adjusting the direction of a puncture channel, the size of a base and length post-output files of the non-closed-loop puncture channel, conducting 3D printing, and obtaining the accurate guiding stent used for cerebral hemorrhage minimally invasive surgery of the patient. The guiding stent has the advantages that customization of individual characters is achieved, positioning is accurate, infection is avoided, the wound is small, the process is simple, and cost is low.

The invention relates to the use of Factor VIIa or a Factor VIIa equivalent for the manufacture of a medicament for preventing complications in ICH patients treated with antiplatelet therapy.

The invention discloses a use of 4,7-dihydrotetrazyl[1,5-alpha]pyrimidine compound and its derivatives in preparation of a drug for prevention or treatment on cerebral hemorrhage. Through a self-created computer-assisted drug molecule design program and virtual screening, it is shown that the 4,7-dihydrotetrazyl[1,5-alpha]pyrimidine compound and its derivatives have a ROCK1 protein inhibitory activity and can be used for treating cerebral hemorrhage. Through further biological activity detection of the screened 4,7-dihydrotetrazyl[1,5-alpha]pyrimidine compound, it is shown that the screened 4,7-dihydrotetrazyl[1,5-alpha]pyrimidine compound has an obvious ROCK1 protein inhibitory activity and has good prevention and treatment effects in an atorvastatin-induced zebra fish cerebral hemorrhage model.

The invention discloses a puncture frame for minimally invasive treatment of cerebral hemorrhage and a manufacturing method. The puncture frame for minimally invasive treatment of cerebral hemorrhagecomprises a head hoop, a top hoop is arranged on the head hoop, and an arch plate is assembled between the head hoop and the top hoop; a puncture needle guide pipe is arranged on the arch plate, and apuncture needle inlet is formed in the arch plate and communicated with the puncture needle guide pipe. The puncture frame has the advantages that the puncture frame for minimally invasive treatmentof cerebral hemorrhage is manufactured in combination with a 3D printing technology, in the cerebral hemorrhage treatment, puncture positioning is simple and precise, entrance is clear and safe, the operation is conveniently conducted, the trauma is small, and the treatment effect is clear; the level difference of different surgical physicians during cerebral hemorrhage treatment can be eliminated, the standardization or homogenization treatment aim is achieved, and it is estimated that the success rate of the brainstem hemorrhage operation can reach above 95%.

The invention discloses a cerebral hemorrhage and cerebral ischemia distinguishing system based on non-contact magnetic induction. The cerebral hemorrhage and cerebral ischemia distinguishing system comprises a signal generator, a power amplifier, a transmitting coil, a receiving coil, a data collection card and a computer. The transmitting coil and the receiving coil are square, are the same in size and are parallel. A detected head is placed in the space of the middle of the two coils. Signals output by the receiving coil and reference signals output by the signal generator are connected to the two input ends of the data collection card. The electric conductivity of the detected head can be reflected by measuring the phase difference between the signals at the two input ends of the data collection card. Due to the fact that the direction of integrated brain electric conductivity changes caused by cerebral hemorrhage is opposite to the direction of integrated brain electric conductivity changes caused by cerebral ischemia, the cerebral hemorrhage and cerebral ischemia distinguishing system achieves non-contact novel magnetic induction detection, and is free of wounds, easy and convenient to use and capable of achieving rapid measurement.

A minimally invasive surgery device for image-guided removal of lesions in the brain by providing suction and irrigation through a small cranial opening. One particular use is for evacuation of intracerebral hemorrhage. Other uses may include evacuation of pus from an abscess, or cystic fluid or necrotic debris from a tumor.

The present invention provides novel 2-pyridinyl[7(pyridin-4-yl)pyrazolo[1,5-a]pyrimidin-3-yl]methanones with at least one substituent on both the 2- and 4-pyridinyl ring having the chemical structure of formula I: The invention further provides compositions and methods employing the novel 2-pyridinyl[7-(pyridin-4-yl)pyrazolo[1,5-a]pyrimidin-3-yl]methanones of formula I to modulate GABA and GABAA receptor physiology to elicit therapeutic responses in mammalian subjects to alleviate neurological or psychiatric disorders, including stroke, head trauma, epilepsy, pain, migraine, mood disorders, anxiety, post traumatic stress disorder, obsessive compulsive disorders, mania, bipolar disorders, schizophrenia, seizures, convulsions, tinnitus, neurodegenerative disorders including Alzheimer's disease, amyotrophic lateral sclerosis and Parkinson's disease, Huntington's chorea, depression, bipolar disorders, mania, trigeminal and other neuralgia, neuropathic pain, hypertension, cerebral ischemia, cardiac arrhythmia, myotonia, substance abuse, myoclonus, essential tremor, dyskinesia and other movement disorders, neonatal cerebral hemorrhage, and spasticity, as well as other psychiatric and neurological disorders mediated by GABA and / or GABAA receptors.

The invention discloses a Chinese drug for curing sequelae of cerebral hemorrhage, cerebral infarction and cerebral thrombosis, which relates to a Chinese drug for the treatment of cardio-cerebrovascular diseases. The invention solves the problem of high drug dependence on the prior drug for curing the sequelae of the cerebral hemorrhage, the cerebral infarction and the cerebral thrombosis. The Chinese drug for curing the sequelae of the cerebral hemorrhage, the cerebral infarction and the cerebral thrombosis of the invention comprises the drugs calculated according to the amounts by weight that 10 to 20 parts of antelope horn, 15 to 25 parts of whole worm, 10 to 20 parts of uncaria atem with hooks, 15 to 25 parts of batryticated silkworm, 10 to 20 parts of giant typhomium tuber, 15 to 25 parts of cassia twig, 10 to 20 parts of ledebouriella root, 10 to 25 parts of frankincense, 10 to 20 parts of Chinese ephedra, 15 to 30 parts of gastrodia tuber, 3 to 7.5 parts of musk and 15 to 25 parts of Chinese angelica root. The total curative ratio of the Chinese drug for curing the sequelae of the cerebral hemorrhage, the cerebral infarction and the cerebral thrombosis of the invention is 40 percent, the total effective rate is 93.3 percent, and the patient has no drug dependence on the Chinese drug of invention.

The present invention relates to compounds of formula (I) and their pharmaceutical compositions. In addition, the present invention relates to therapeutic methods for the treatment and / or prevention of Aβ-related pathologies such as Down's syndrome, β-amyloid angiopathy such as but not limited to cerebral amyloid angiopathy or hereditary cerebral hemorrhage, disorders associated with cognitive impairment such as but not limited to MCI (“mild cognitive impairment”), Alzheimer's disease, memory loss, attention deficit symptoms associated with Alzheimer's disease, neurodegeneration associated with diseases such as Alzheimer's disease or dementia including dementia of mixed vascular and degenerative origin, pre-senile dementia, senile dementia and dementia associated with Parkinson's disease, progressive supranuclear palsy or cortical basal degeneration.

An application of the brasileiin in preparing the medicines for treating the cerebral ischemia, encephalorrhagia and the cerebral disfunction caused by excessive peroxide in cerebral tissue is disclosed.

The invention relates to a traditional Chinese medicine sharpening-mind and inducing-consciousness microemulsion nasal cavity spraying agent and a preparation method thereof. The traditional Chinese medicine sharpening-mind and inducing-consciousness microemulsion nasal cavity spraying agent comprises 10 to 20 parts of artificial musk, 2 to 8 parts of borneol, 30 to 40 parts of turmeric, 40 to 50 parts of gardenia, 10 to 20 parts of polyoxyethylene-9-laurel ether, 5 to 8 parts of sulfo-lauryl alcohol, 1 to 6 parts of yolk phospholipid, 1 to 4 parts of lecithin, 2 to 10 parts of bean phospholipid, 2 to 4 parts of vitamin E, 10 to 30 parts of refined soybean oil, 10 to 20 parts of 1,2-propylene glycol, 10 to 15 parts of glycerol, 2 to 4 parts of cholic acid, a right amount of ethanol, a right amount of purified water, a right amount of essence and a right amount of propellant. The traditional Chinese medicine sharpening-mind and inducing-consciousness microemulsion nasal cavity spraying agent has the functions of clearing away heat and toxic material, removing heat from the blood, cooling blood, promoting blood circulation, sharpening mind and inducing consciousness, is natural, innoxious, safe, effective and biodegradable, is clinically used for treating various cerebrovascular diseases and is especially effective to central coma diseases, such as disturbance of consciousness, serious symptom craniocerebral injury, cerebral hemorrhage, cerebral infarction, drug poisoning, and the like; and the medicine realizes cerebral targeting administration by the approach of a nose, can break through blood-brain barriers, can rapidly exert actions and also has convenient administration.

The invention discloses collagen-containing compound nutritious powder, which consists of collagens, oil powder, tartary buckwheat flour, kudzuvine root, pseudo-ginseng powder, cocoa powder and protein sugar. The oil powder of the collagen-containing compound nutritious powder contains fatty acids and vitamins required by human bodies, can achieve the effect of recovering physical abilities of sub-healthy people as soon as possible, and is suitable for long-term consumption to supplement the deficient vitamins and fatty acid Omega 3, effectively prevent cardiovascular diseases, achieve important effects on the prevention and cerebral apoplexy and intracerebral hemorrhage and simultaneously achieve a good effect on the expelling of toxins. The collagens of the collagen-containing compound nutritious powder have the effect of supplementing proteins and amino acids. The tartary buckwheat of the collagen-containing compound nutritious powder has the effects of improving microcirculation, enhancing islet beta cellular nutrition and metabolism, retarding the decomposition of polysaccharides and the absorption of glucose and keeping good defaecation. The pseudo-ginseng powder of the collagen-containing compound nutritious powder has the effects of lowering blood pressure, regulating a blood sugar level and reducing blood fat. The kudzuvine root of the collagen-containing compound nutritious powder has the effects of heat clearing, internal heat decreasing, disintoxication, blood pressure lowering and the like.

The invention discloses a visible cerebral ventricle and subdural external drainage system. The visible cerebral ventricle and subdural external drainage system comprises a visible cerebral ventricle puncture system and a drainage system. The visible cerebral ventricle puncture system comprises a visible puncture guiding core, and LED light sources and a miniature camera are coaxially arranged at the intracranial end of the visible puncture guiding core. The wall of a puncture sheath is see-through, and millimeter scales are arranged on the outer wall of the puncture sheath. The visible cerebral ventricle and subdural external drainage system has the remarkable advantages that as the miniature camera can be connected to one end of the visible puncture guiding core, and a monitor is connected to the other end of the visible puncture guiding core, cerebral puncture is completely performed in a direct-viewing mode, precision is improved, and it is avoided that due to operation based on a rule of thumb, the cerebral tissue is damaged, or cerebral hemorrhage occurs. As miniature vanes (fixing clamps) are arranged at the position distant from the cerebral ventricle by 10 cm-15 cm and used for fixing a drainage tube at the incised skin, the defect that a drainage tube used for the current clinic is simply bound and fixed through threads is overcome.

The invention relates to methods of treating stroke comprising administration of a VLA-4 antagonist to a subject after the onset of the stroke, e.g., ischemic stroke (e.g., acute ischemic stroke) or hemorrhagic stroke (e.g., intracerebral hemorrhage), sub-arachnoid hemorrhage, or traumatic brain injury. Kits and articles of manufacture are also described herein.

The present invention relates to novel compounds of formula I and therapeutically acceptable salts thereof, their pharmaceutical compositions, processes for making them and their use as therapeutic methods for treatment and / or prevention of various diseases. In particular the invention relates to compounds, which inhibit the Aβ40 and Aβ42 production, increase the Aβ37 and Aβ38 production and maintain the Notch signaling and will be used for treatment and / or prevention of Aβ-related pathologies such as Alzheimer's disease, Downs syndrome and β-amyloid angiopathy, such as but not limited to cerebral amyloid angiopathy, hereditary cerebral hemorrhage, disorders associated with cognitive impairment, such as but not limited to MCI (“mild cognitive impairment”), Alzheimer's disease, memory loss, attention deficit symptoms associated with Alzheimer's disease, neurodegeneration associated with diseases such as Alzheimer's disease or dementia including dementia of mixed vascular and degenerative origin, pre-senile dementia, senile dementia and dementia associated with Parkinson's disease, progressive supranuclear palsy or cortical basal degeneration.

Disclosed herein are compounds, compositions and methods for preventing and treating diseases such as intracerebral hemorrhage, cancer, or conditions associated with damaged cells, activated lymphocytes, or microbial products. The disclosed compounds are curcumin analogs. The curcumin analogs possess anti-inflammatory and antioxidant properties, which in part, reduce AP-1 and NF-κB activity.